CNA – Samsung BioLogics yesterday denied a media report that said the South Korean firm was in talks to buy United States (US) drugmaker Biogen. Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen approached Samsung to buy its shares, which could be valued at over USD42 billion. Biogen is valued at
